Abstract: A novel method of providing virtual private access to a software defined data center (SDDC) is provided. The SDDC uses distributed VPN tunneling to allow external access to application services hosted in the SDDC. The SDDC includes host machines for providing computing and networking resources and a VPN gateway for providing external access to those resources. The host machines that host the VMs running the applications that VPN clients are interested in connecting performs the VPN encryption and decryption. The VPN gateway does not perform any encryption and decryption operations. The packet structure is such that the VPN gateway can read the IP address of the VM without decrypting the packet.

Abstract: A novel method of providing virtual private access to a software defined data center (SDDC) is provided. The SDDC uses distributed VPN tunneling to allow external access to application services hosted in the SDDC. The SDDC includes host machines for providing computing and networking resources and a VPN gateway for providing external access to those resources. The host machines that host the VMs running the applications that VPN clients are interested in connecting performs the VPN encryption and decryption. The VPN gateway does not perform any encryption and decryption operations. The packet structure is such that the VPN gateway can read the IP address of the VM without decrypting the packet.

Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.

Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.

Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.

Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.

Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.

Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.

Abstract: This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.

Abstract: A method and system for documenting and managing patient information in real time for accurate medical examination and treatment of a patient is provided. An information carrier device that stores patient information is provided to the patient. A data extraction unit extracts the stored patient information from the information carrier device and transmits the extracted patient information to a patient information processing system. A recording unit records observational data comprising medical examination information and information on treatment prescribed for the patient.

Abstract: Highly shelf-stable electrically assisted transdermal drug delivery systems for delivering epinephrine, typically with an anesthetic such as lidocaine, are provided along with methods for making the highly shelf-stable epinephrine-containing transdermal delivery device. Highly shelf-stable packaged electrode assemblies for transdermal delivery of epinephrine also are provided.

Abstract: A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.